Applied Therapeutics, Inc.

NasdaqCM:APLT Stok Raporu

Piyasa değeri: US$15.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Applied Therapeutics CEO'su Les Funtleyder, Nov2023 tarihinde atandı, in görev süresi 2.25 yıldır. in toplam yıllık tazminatı $ 1.05M olup, şirket hissesi ve opsiyonları dahil olmak üzere 50.4% maaş ve 49.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.33% ine doğrudan sahiptir ve bu hisseler $ 51.70K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.5 yıl ve 7.9 yıldır.

Anahtar bilgiler

Les Funtleyder

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi50.35%
CEO görev süresi2.3yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi1.5yrs
Yönetim Kurulu ortalama görev süresi7.9yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Jul 15

Here's Why Applied Therapeutics (NASDAQ:APLT) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Nov 15

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Applied...
Seeking Alpha • Sep 18

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Summary FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible administrative actions of NDA filing submission of govorestat for the treatment of patients with SORD deficiency. If the pre-NDA meeting of govorestat for SORD deficiency goes well, then the company would be in a good position to file an NDA for this drug in Q1 of 2025. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Applied Therapeutics: Pushing Towards FDA Approval

Summary Today, we revisit clinical stage developmental concern Applied Therapeutics, Inc. for the first time in 2024. The company is moving towards its first FDA approval before yearend, and could garner another approval for a different indication in 2025. An updated analysis around Applied Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 01

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Applied...
Seeking Alpha • May 28

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Summary Applied Therapeutics develops govorestat for rare diseases and AT-001 for diabetic cardiomyopathy; both are aldose reductase inhibitors. Govorestat shows promise as a treatment for galactosemia by preventing galactose conversion. AT-001’s efficacy in diabetic cardiomyopathy is inconclusive; significant results are only in certain subgroups. Hold APLT stock due to high risks despite potential in niche markets; it's suitable for a diversified high-risk portfolio segment. Read the full article on Seeking Alpha
Seeking Alpha • Feb 16

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Summary Positive 12-month interim results from the phase 3 INSPIRE study using govorestat for the treatment of patients with SORD deficiency achieved. Pre-NDA meeting with FDA to be sought out after to see if an NDA submission of govorestat for SORD deficiency could be done with only the positive 12-month interim data. 24-month interim results from the phase 3 INSPIRE study, using govorestat for the treatment of patients with SORD deficiency, is the next data readout to be expected. The NDA of govorestat for galactosemia has been submitted by the FDA and the EMA has validated the MAA; There is a good chance that Applied Therapeutics could receive regulatory approval for one or both of these territories. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Applied Therapeutics...
Analiz Makalesi • Nov 13

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Applied Therapeutics...
Analiz Makalesi • Aug 11

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • May 19

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 19

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Applied Therapeutics shares were hammered this month after FDA did not agree to accelerated approval for its drug candidate AT-007 in treating galactosemia in children. Investors and sell-side analysts are completely discounting the potential of the pipeline. Even in a conservative scenario, shares could reach $165 by 2028 or 38x upside potential. I provide various scenarios and my calculations on revenue potential, and enterprise value potential.
Analiz Makalesi • Nov 11

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Aug 13

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • May 15

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Feb 26

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Investors who take an interest in Applied Therapeutics, Inc. ( NASDAQ:APLT ) should definitely note that the...

CEO Tazminat Analizi

Les Funtleyder'un ücretlendirmesi Applied Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2025n/an/a

-US$18m

Jun 30 2025n/an/a

-US$68m

Mar 31 2025n/an/a

-US$44m

Dec 31 2024US$1mUS$531k

-US$106m

Sep 30 2024n/an/a

-US$187m

Jun 30 2024n/an/a

-US$161m

Mar 31 2024n/an/a

-US$194m

Dec 31 2023US$675kn/a

-US$120m

Sep 30 2023n/an/a

-US$97m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$80kn/a

-US$83m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$229kn/a

-US$106m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$104m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$94m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$625kn/a

-US$46m

Tazminat ve Piyasa: Les 'nin toplam tazminatı ($USD 1.05M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 624.15K ).

Tazminat ve Kazançlar: Les şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Les Funtleyder (55 yo)

2.3yrs
Görev süresi
US$1,053,846
Tazminat

Mr. Les D. Funtleyder has been an Independent Director of Reviva Pharmaceuticals Holdings, Inc. since December 8, 2020. Mr. Funtleyder served as Interm CEO, CFO, Principal Financial Officer & Independent D...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Les Funtleyder
Interm CEO2.3yrsUS$1.05m0.33%
$ 51.7k
Corwin Hooks
Chief Commercial Officer1.8yrsUS$2.18m0.053%
$ 8.4k
Constantine Chinoporos
COO & Chief Business Officer2.2yrsVeri yok0.051%
$ 8.0k
Catherine Thorpe
Interim Chief Accounting Officer2.7yrsVeri yokVeri yok
Reena Colacot
Head of Quality1.1yrsVeri yokVeri yok
Todd Baumgartner
Chief Regulatory Officerless than a yearVeri yokVeri yok
Evan Bailey
Chief Medical Officerless than a yearVeri yok0.36%
$ 55.7k
Dottie Caplan
Executive Vice President of Patient Advocacy & Government Affairs.less than a yearVeri yokVeri yok
1.5yrs
Ortalama Görev Süresi
58.5yo
Ortalama Yaş

Deneyimli Yönetim: APLT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Les Funtleyder
Interm CEO9.7yrsUS$1.05m0.33%
$ 51.7k
Jay Skyler
Independent Director6.8yrsUS$267.50k0.035%
$ 5.5k
Lawrence Steinman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Teena Lerner
Lead Independent Director8.9yrsUS$265.00k0.069%
$ 10.8k
Stacy Kanter
Independent Director6.8yrsUS$267.50k0.035%
$ 5.5k
Gregg Stone
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Donald Landry
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
Donald D'Amico
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Roy Freeman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Roxana Mehran
Member of Scientific Advisory Boardno dataVeri yokVeri yok
7.9yrs
Ortalama Görev Süresi
69yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: APLT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/02/02 16:45
Gün Sonu Hisse Fiyatı2026/02/02 00:00
Kazançlar2025/09/30
Yıllık Kazançlar2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Applied Therapeutics, Inc. 7 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Carter GouldBarclays
Paul ChoiGoldman Sachs
Luke DavisRBC Capital Markets